Nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator. Shows potent cardiovascular effects. Improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Exhibits potent vasodilator and antiplatelet activity. Anti-aggregating agent.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
C36H39NO5 . HCl
Purity: >98% (NMR)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle: J.P. Stasch, et al.; Br. J. Pharmacol. 136, 773 (2002)
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase: P. Schmidt, et al.; Eur. J. Pharmacol. 468, 167 (2003)
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease: G. Boerrigter & JC. Burnett Jr.; Cardiovasc. Drug Rev. 25, 30 (2007) (Review)
Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers: R. Frey, et al.; J. Clin. Pharmacol. 48, 1400 (2008)
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts: T. Krieg, et al.; Eur. Heart J. 30, 1607 (2009)
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure: H. Lapp, et al.; Circulation 119, 2781 (2009)
Role of guanylate cyclase modulators in decompensated heart failure: V. Mitrovic, et al.; Heart Fail. Rev. 14, 309 (2009) (Review)
Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure: J. Tamargo, et al.; Curr. Opin. Investig. Drugs 11, 1039 (2010)
Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase: S. Roger, et al.; Vascul. Pharmacol. 53, 281 (2010)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|